Advertisement

Topics

Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment

19:05 EDT 23 May 2017 | Drugs.com

King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate), an improved ultramicrosize...

Original Article: Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment

NEXT ARTICLE

More From BioPortfolio on "Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...